Gene Silencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Gene Silencing Market is projected to expand from USD 2.91 Billion in 2025 to USD 4.48 Billion by 2031, reflecting a compound annual growth rate of 7.46%. This therapeutic field focuses on the precise downregulation of specific disease-causing genes, predominantly employing mechanisms such as antisense oligonucleotides and RNA interference. The market's growth is fundamentally fueled by the increasing prevalence of oncological conditions and chronic genetic disorders that require targeted molecular interventions, alongside significant progress in lipid nanoparticle delivery technologies. According to the 'American Society of Gene & Cell Therapy', the industry saw strong developmental momentum in '2025', evidenced by the initiation of 38 new clinical trials dedicated to RNA therapies during the second quarter alone.

Despite these advancements, the sector encounters substantial hurdles regarding the stability and intracellular delivery of silencing agents. The physiological degradation of RNA molecules within the bloodstream, combined with the challenge of transporting large macromolecules across cellular membranes without causing off-target toxicity, remains a critical obstacle. These technical difficulties continue to impede the broad commercialization and clinical efficacy of these therapies, representing major barriers that limit the widespread adoption of gene silencing treatments.

Market Drivers

Accelerated regulatory approvals and expanding clinical pipelines act as the primary catalyst for the Global Gene Silencing Market, shifting the sector from experimental research to tangible commercial realization. As regulatory agencies confirm the safety profiles of antisense and RNA interference modalities, the market entry of novel therapies has quickened, specifically addressing unmet needs in rare genetic diseases. This momentum was evident when, according to Biopharma PEG, the FDA approved Tryngolza in December 2024, a first-in-class RNA-targeted medicine for familial chylomicronemia syndrome. The financial viability of the sector is further validated by commercial scalability; for instance, according to Alnylam Pharmaceuticals, the company reported third-quarter net product revenues of $851 million in October 2025, marking a 103% year-over-year increase that underscores the strong demand for effective gene silencing interventions.

Concurrently, strategic partnerships and collaborations are reshaping market dynamics as major pharmaceutical companies strive to overcome persistent intracellular delivery challenges. By acquiring specialized biotechnology firms, industry leaders gain immediate access to proprietary delivery platforms - such as antibody oligonucleotide conjugates - that can target tissues like muscle beyond the liver. This trend of high-value consolidation is exemplified by Novartis, which, according to reports in October 2025, agreed to acquire Avidity Biosciences for approximately $12 billion to secure its advanced RNA architecture. These capital-intensive collaborations provide the necessary funding to navigate complex clinical trials and accelerate the development of next-generation modalities, ensuring sustainable long-term market expansion.

Market Challenges

The persistent difficulty regarding the stability and intracellular delivery of silencing agents acts as a critical bottleneck restricting the expansion of the Global Gene Silencing Market. Although RNA therapies offer significant therapeutic promise, the technical inability to transport large macromolecules across cellular membranes without toxicity or degradation frequently results in clinical failures. These delivery barriers increase the risk profile of developmental programs, leading to significant attrition in late-stage trials and complicating the path to regulatory approval. Consequently, the timeline for commercialization is significantly prolonged, delaying the entry of potentially curative treatments into the healthcare system.

This high-risk environment directly impacts the financial ecosystem required for market growth, as investors exercise greater caution toward early-stage ventures grappling with these unresolved technical hurdles. A contraction in available capital for foundational research stalls the progression of pipeline candidates into commercially viable treatments. According to the 'American Society of Gene & Cell Therapy', in '2025', start-up financings raised only $197 million in the second quarter, reflecting a continued decline in investment volume for the sector. This reduction in essential funding impedes the industry's ability to innovate, thereby hampering the overall trajectory of the market.

Market Trends

The rise of RNA-based biopesticides and crop protection in agriculture signifies a transformative expansion of the market, applying gene silencing principles to sustainable pest management. Unlike broad-spectrum chemical agents, these biodegradable solutions employ double-stranded RNA to selectively silence essential genes in specific agricultural pests, thereby minimizing environmental toxicity and preserving beneficial insects. This commercial breakthrough was highlighted when, according to GreenLight Biosciences, the company received registration from the U.S. Environmental Protection Agency in October 2025 for Norroa, a novel RNA-based solution specifically designed to control and target Varroa mites in honeybee colonies.

Simultaneously, the emergence of epigenetic and transcriptional gene silencing is establishing a new therapeutic paradigm that achieves durable gene repression without altering the underlying DNA sequence. This approach leverages epigenetic editors to modulate chemical markers, such as methylation patterns, effectively turning off disease-associated genes at the transcriptional level while avoiding the safety risks associated with double-strand DNA breaks. The investment community has recognized the potential of this modality; for instance, according to Epigenic Therapeutics, in September 2025, the company completed a $60 million Series B financing round to accelerate the clinical development of its proprietary gene modulation platform.

Key Players Profiled in the Gene Silencing Market

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories:

Gene Silencing Market, by Product & Service:

• RNAi
• CRISPR-Cas9
• Antisense Oligonucleotides
• Others

Gene Silencing Market, by Application:

• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Therapeutics Manufacturing
• Others

Gene Silencing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.